Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics borrows $750 million term loan due 2031, repays earlier loans

Neutral Impact 4 of 5 financing Written later

TG Therapeutics entered a first amendment to its financing agreement on March 18, 2026, establishing a $750 million term loan maturing March 18, 2031, fully borrowed at closing, with part of the proceeds used to repay the existing Initial Term Loans in full. The filing also sets up an uncommitted additional facility of up to $250 million, and the loan is secured by substantially all assets of the company and its guarantor subsidiaries.

Key points

  • $750 million 2026 Term Loan borrowed in full on March 18, 2026, with proceeds partly used to repay Initial Term Loans
  • Loan matures March 18, 2031; quarterly amortization of $37.5 million begins with the quarter ending March 31, 2030
  • Pricing grid starts at 4.75% for SOFR borrowings and 3.75% for base rate borrowings, with a 25 basis point step-down tied to leverage
  • Uncommitted additional facility of up to $250 million; Blue Owl Capital Corporation is administrative agent

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECMar 20, 2026, 4:33 PM ET
Accession number0001437749-26-009253

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 20, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.